سعر دولوكسبرين 60مجم 28 كبسولة 2024

Duloxeprin 60 mg capsules (duloxetine 60 mg), Future Pharmaceutical Industries (FPI) / Utopia Pharmaceuticals, Egypt.

• Major depressive disorder (MDD) in adults.Population: AdultsDailyMed / FDA
• Generalized anxiety disorder (GAD) in adults (and pediatric patients 7+ per US label).Population: Adults / pediatrics as labeledDailyMed / FDA
• Diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain in adults (US-approved).Population: AdultsDailyMed / FDA

• Most common in adults (≥5% and ≥2× placebo): nausea, dry mouth, somnolence, constipation, decreased appetite, hyperhidrosis.International label, same formulation · DailyMed / FDA

• Concomitant MAOI antidepressants, use within 14 days of stopping an MAOI, or initiation in patients on linezolid/IV methylene blue (serotonin syndrome risk).International label, same formulation · DailyMed / FDA

• Boxed warning: antidepressants increase risk of suicidal thinking and behavior in children, adolescents, and young adults; monitor all patients for worsening and suicidality.International label, same formulation · DailyMed / FDA
• Hepatotoxicity (including fatal hepatic failure reported): discontinue if jaundice or significant liver dysfunction; avoid in substantial alcohol use or chronic liver disease.International label, same formulation · DailyMed / FDA
• Serotonin syndrome risk with other serotonergic drugs; increased bleeding risk with NSAIDs/aspirin/anticoagulants; orthostatic hypotension/falls; discontinuation syndrome — taper gradually.International label, same formulation · DailyMed / FDA

• MAOI antidepressants / linezolid / IV methylene blueMajorMAOI antidepressants / linezolid / IV methylene blue: contraindicated (serotonin syndrome).DailyMed / FDA
• Potent CYP1A2 inhibitors (e.g. fluvoxamine, ciprofloxacin)MajorPotent CYP1A2 inhibitors (e.g. fluvoxamine, ciprofloxacin): avoid — markedly increases duloxetine exposure.DailyMed / FDA
• NSAIDs / aspirin / warfarinModerateNSAIDs / aspirin / warfarin: increased bleeding risk; monitor.DailyMed / FDA

• Third-trimester SNRI/SSRI exposure may cause neonatal poor adaptation (respiratory distress, feeding difficulty, hypotonia, irritability). Use in month before delivery associated with increased postpartum hemorrhage risk.International label, same formulation · DailyMed / FDA
• Present in human milk; monitor infants for sedation, poor feeding, and poor weight gain.International label, same formulation · DailyMed / FDA

English text not available for this section.